Founded in 1999, Chongqing Haifu (HIFU) Technology Co. Ltd.

is
headquartered in Chongqing China and keeps being a world-leading
manufacturer of non-invasive ultrasound therapeutic systems for both
malignant and benign tumors. Her employee pool exceeds 300 persons
including top-class experts in HIFU field.

Cooperating with Chongqing Medical University and its affiliated hospitals,

Haifu has established an innovational operation mode integrated of
manufacturing, marketing, R&D, and education. These would lead to
effective treatment for fibroids and patients suffering from cancer,
osteosarcoma and other kinds of tumors.

In October 2005, National Engineering Research Center of Ultrasound

Medicine was set up by Haifu, playing an important role of transformation
base of R&D, engineering and clinical medicine. Until now, it is still the only
one National Engineering Research Center approved by National
Development and Reform Commission of China in the field of digital medical
device.

The Clinical Training Center, authorized by China Ministry of Health and

situated in the 2nd Affiliated Hospital of Chongqing Medical University, has
trained and qualified a large number of doctors for non-invasive Ultrasound
Ablation from 13 countries and regions.

Furthermore, there are consistently academic relationships between Haifu

and foreign organizations, such as University of Oxford (UK), University of
Utah (USA), University of Chiba (Japan), Catholic University of Korea (S.
Korea), University of Hong Kong (China), etc.

Equipped with original innovation ability and independent intellectual

property right, Haifu has established win-win cooperation with some
multinational companies such as Siemens, Esaote, Olympus, and etc. Haifu
and Siemens Medical Solutions have been jointly developing a MRI-guided
Focused Ultrasound Tumor Therapeutic System. The primary consequences
of this collaboration will be an important development in the treatment of
malignant and benign tumors, such as uterine fibroids and osteosarcoma.

Moreover, from over 20 years’ HIFU R&D experience, Haifu has developed a
series of products including the CE marked Haifu?R Model JC Focused
Ultrasound Tumor Therapeutic System, the CE marked Haifu?R Model
JC200 Focused Ultrasound Tumor Therapeutic System, the SeapostarTM
Ultrasound Therapeutic Device for Gynecological Diseases and the
SeapopinnaTM Ultrasound Therapeutic Device for Rhinitis. Haifu products
have been installed in United Kingdom, Russia, Spain, Hong Kong China,
Italy, Japan, Korea, Mainland of China, Romania, Saudi Arabia, Ukraine and
etc.

The Haifu Model JC Focused Ultrasound Tumor Therapeutic System offers

non-invasive treatment of solid tumors including primary and metastatic
liver cancer, breast cancer, primary and metastatic malignant bone tumors,
soft tissue sarcomas, and benign tumors such as uterine fibroids and breast
fibroadenomas; meanwhile it could be used for pain relief of patients with
advanced-stage malignant tumors. The Haifu?R Model JC200 Focused
Ultrasound Tumor Therapeutic System offers non-invasive treatment of
uterine fibroids to reserve the patients’ uterus and ablate the fibroids
extracoporeally.

National Engineering Research Centre

Research Building
Products:
Haifu Model JC Focused Ultrasound
Tumor Therapeutic System

Non-invasive, extracorporeal ultrasound ablation treatment of tumors

INDICATIONS

• Malignant tumors:
o Liver
o Kidney
o Breast
o Pancreas
o Bone
o Soft Tissue
o Metastatic cancers
• Benign tumors:
o Uterine Fibroids
o Uterine adenomyosis
o Breast Fibroadenoma

ADVANTAGES

• One time treatment

• Non-invasive treatment
• Real-time US-guided Procedure
• Low cost
• Short hospital stay
• Minor complications
• Not limited by tumor size
 • No radioactive pollution or injury

APPROVALS
• Europe: CE
• China: SFDA
• Korea: KFDA
• Russian Federation approval

Haifu Model JC200 Focused

Ultrasound Tumor Therapeutic
System
 • Non-invasive Treatment of Uterine Fibroids
• CE-marked Ultrasound Therapeutic System

INDICATIONS

• Uterine Fibroids
• Uterine adenomyosis

FEATURES

• Outpatient basis with quick recovery

• Only conscious sedation, no anesthesia required
• No surgical cut, no bleeding or blood transfusion
• Immediate coagulation necrosis of fibroids
• Great alleviation of symptoms, evident reduction of fibroids

ADVANTAGES

• One time treatment

• Real-time US-guided Procedure
• Low cost
• No hospital stay
• No radioactive pollution or injury

APPROVALS

• Europe: CE
• China: SFDA
• Korea: KFDA
SeapostarTM Model CZF Ultrasound
Therapeutic Device

Non-invasive Treatment for Gynaecological Diseases

INDICATIONS

• Non-neoplastic epithelial disorders of vulva.

• Chronic cervicitis:
o Cervical ectopy (cervical erosion).
o Cervical cysts
o Cervical hypertrophy
• Vulval condyloma acuminatum

FEATURES

• Non-invasive Treatment: Protecting and maintaining physiological

functions and biological structure of cervix.
• Safe Treatment: No post-treatment decrustation or scars.
• Patient-friendly Treatment: out-patient procedure.

ADVANTAGES

• Low recurrence rate.

• Quick recovery
 • Low cost.
• No smog or ionizing radiation

SeapopinnaTM Model CZB

Ultrasound Therapeutic Device for
Rhinitis

INDICATION

• Allergic rhinitis.

FEATURES

• Non-invasive Treatment: No surgical wound, no foreign object implanting,

no additional harm.
 • Patient-friendly Treatment: An outpatient procedure, no nasal packing.
• Convenient Data Management: Capacity of 40,000 patient records.

ADVANTAGES

• Safe: protecting and maintaining the structure of nasal cavity and nasal
mucosa without any nose bleed, adhesion of nasal cavity, mycteroxerosis
or postnasal drip.
• Repeatable: flexible clinical protocol for individuals.
• User-friendly: 5-10mins treatment, easy to command.
• Environment-friendly: no radioactive pollution or smog.